Efficacy of Omalizumab against Japanese Cedar pollinosis in clinical practice.

ABSTRACT:

Background

Japanese cedar pollinosis (JCP), which affects over 40% of the population and represents a major public health issue in Japan, has various treatment options, but limited clinical reports and high costs necessitate careful patient selection. This study aimed to evaluate the efficacy of omalizumab in treating JCP and identify key considerations for its appropriate clinical application.

Methods

We retrospectively analyzed 42 patients with JCP treated with omalizumab from 2021 to 2024. Treatment response was assessed using a 3-category patient-reported scale across all years. In a 2023-2024 subset (n = 23), quantitative total symptom score (TSS) data were available, allowing effect-size estimation and subgroup analyses.

Results

The study included 42 patients (3

SUBMITTER: Takeda M 

PROVIDER: S-EPMC12664126 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature